Q32 Bio (NASDAQ:QTTB) Posts Earnings Results, Beats Expectations By $0.14 EPS

Posted by Francis Steltz on May 5th, 2026

Q32 Bio (NASDAQ:QTTB – Get Free Report) released its earnings results on Tuesday. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.14, FiscalAI reports.

Q32 Bio Trading Down 0.4%

QTTB stock traded down $0.02 on Tuesday, reaching $5.02. The company’s stock had a trading volume of 75,979 shares, compared to its average volume of 255,898. The business has a fifty day simple moving average of $5.85 and a two-hundred day simple moving average of $4.14. Q32 Bio has a 12-month low of $1.35 and a 12-month high of $8.05. The firm has a market cap of $78.46 million, a PE ratio of 2.18 and a beta of -0.05. The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.85 and a current ratio of 4.85.

Insider Buying and Selling

In other Q32 Bio news, CEO Jodie Pope Morrison sold 9,896 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $4.51, for a total value of $44,630.96. Following the completion of the transaction, the chief executive officer owned 89,104 shares in the company, valued at approximately $401,859.04. This represents a 10.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 16,706 shares of company stock valued at $75,344 over the last ninety days. Company insiders own 40.00% of the company’s stock.

Hedge Funds Weigh In On Q32 Bio

Institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP bought a new position in Q32 Bio in the second quarter worth $25,000. Acadian Asset Management LLC bought a new position in Q32 Bio in the first quarter worth $50,000. Two Sigma Investments LP bought a new position in Q32 Bio in the third quarter worth $62,000. ADAR1 Capital Management LLC bought a new position in Q32 Bio in the fourth quarter worth $66,000. Finally, AQR Capital Management LLC bought a new position in Q32 Bio in the first quarter worth $68,000. Institutional investors own 31.32% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on QTTB shares. Zacks Research upgraded Q32 Bio from a “hold” rating to a “strong-buy” rating in a research note on Thursday, March 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Q32 Bio in a research note on Friday, January 9th. Finally, HC Wainwright restated a “buy” rating and issued a $13.00 price objective on shares of Q32 Bio in a research note on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Read Our Latest Report on Q32 Bio

Q32 Bio Company Profile

(Get Free Report)

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.